Compare XP & TECH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XP | TECH |
|---|---|---|
| Founded | 2001 | 1976 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1B | 9.5B |
| IPO Year | 2019 | 1989 |
| Metric | XP | TECH |
|---|---|---|
| Price | $17.61 | $58.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 14 |
| Target Price | $22.40 | ★ $71.23 |
| AVG Volume (30 Days) | ★ 8.8M | 1.8M |
| Earning Date | 11-17-2025 | 02-04-2026 |
| Dividend Yield | ★ 1.03% | 0.55% |
| EPS Growth | ★ 18.53 | N/A |
| EPS | ★ 1.76 | 0.49 |
| Revenue | ★ $3,229,174,949.00 | $1,216,732,000.00 |
| Revenue This Year | $17.71 | $2.33 |
| Revenue Next Year | $13.05 | $7.05 |
| P/E Ratio | ★ $9.92 | $120.21 |
| Revenue Growth | ★ 8.33 | 3.85 |
| 52 Week Low | $10.82 | $46.01 |
| 52 Week High | $20.64 | $79.28 |
| Indicator | XP | TECH |
|---|---|---|
| Relative Strength Index (RSI) | 43.89 | 42.18 |
| Support Level | $17.37 | $58.75 |
| Resistance Level | $18.12 | $61.20 |
| Average True Range (ATR) | 0.71 | 2.01 |
| MACD | -0.20 | -0.54 |
| Stochastic Oscillator | 8.76 | 13.44 |
XP Inc is a Cayman Island-based technology-driven financial services platform. It is a provider of low-fee financial products and services in Brazil. The company evaluates its business through a single segment such as monitoring operations, making decisions on fund allocation, and evaluating the performance. It generates revenue through the Brokerage commission.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.